[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353696-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353696-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-clinicopathological-study-of-borderline-ovarian-tumors-insights-from-a-tertiary-care-center-in-saudi-arabia","A clinicopathological study of borderline ovarian tumors - insights from a tertiary care center in Saudi Arabia","","Borderline ovarian tumors (BOTs) are epithelial neoplasms defined by atypical proliferation without stromal invasion and account for roughly 10–20% of epithelial ovarian malignancies, often diagnosed early with favorable outcomes. Regional evidence, especially from Saudi Arabia, remains limited. A retrospective study reviewed all BOT cases treated at King Faisal Specialist Hospital and Research Center in Jeddah between January 2015 and February 2025, comparing serous and mucinous subtypes using clinical, surgical, pathological, and follow-up data.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-clinicopathological-study-of-borderline-ovarian-tumors-insights-from-a-tertiary-care-center-in-saudi-arabia/353696/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-clinicopathological-study-of-borderline-ovarian-tumors-insights-from-a-tertiary-care-center-in-saudi-arabia/353696.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What distinguishes borderline ovarian tumors from invasive ovarian carcinomas?","Question",{"text":63,"@type":64},"Borderline ovarian tumors show atypical epithelial proliferation but lack destructive stromal invasion, which supports their distinct classification and generally favorable prognosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which clinicopathological features were most common in the reviewed Saudi cohort?",{"text":68,"@type":64},"Most patients were premenopausal, presented with stage I disease, and serous BOT was the predominant subtype. Fertility-sparing surgery was performed in a subset of cases.",{"name":70,"@type":61,"acceptedAnswer":71},"How do serous and mucinous BOT subtypes differ in recurrence and related findings?",{"text":72,"@type":64},"Serous BOTs were significantly associated with bilateral tumors, higher FIGO stage, implants, and recurrence, whereas mucinous BOTs showed higher rates of appendectomy and positive peritoneal cytology.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353696,1790194508,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Baradwan etal. BMC Women's Health (2026) 26:103 BMC Women's Health  \n[https://doi.org/10.1186/s12905-026-04288-3](https://doi.org/10.1186/s12905-026-04288-3)  \nRESEARCH Open Access  \nA clinicopathological study of borderline ovarian tumors: insights from a tertiary care center in Saudi Arabia  \nSaeed Baradwan 1*, Hassan M. Latifah 1, Bandr Hafedh1, Haneen Al-Maghrabi2, Ruzanah Almarzugi1, Wajd Aljabri1 and Alaa Edrees3  \nAbstract  \nBackground Borderline ovarian tumors (BOTs) are a distinct category of epithelial ovarian neoplasms characterized by atypical proliferation without stromal invasion. They account for 10–20% of epithelial ovarian malignancies and are typically diagnosed at early stages in younger women. Despite their generally favorable prognosis, regional data remain limited, particularly from Saudi Arabia.  \nMethods We conducted a retrospective review of all BOT cases managed at King Faisal Specialist Hospital and Research Center, Jeddah, from January 2015 to February 2025. Clinical, surgical, pathological, and follow-up data were collected and analyzed. Comparative analysis was performed between serous and mucinous subtypes.  \nResults A total of 59 patients were included (mean age: 41.8 ± 15.8 years) . Most were premenopausal (71 . 2%) and presented with stage I disease (79 . 7%) . Serous BOT was the predominant subtype (55 . 9%) . Fertility-sparing surgery was performed in 22% of cases. Implants were observed in 25.4%, and microinvasion in 32. 2% . Recurrence occurred in 17% of patients, primarily in the contralateral ovary and peritoneum. Serous BOTs were significantly associated with bilateral tumors, higher FIGO stage (p = 0 . 011), presence of implants (p = 0 . 038), and recurrence (p = 0 . 032), while mucinous BOTs showed higher rates of appendectomy and positive peritoneal cytology. Adjuvant therapy was rarely administered and limited to recurrent cases (n = 2/10) . Notably, 2 patients (3 .4%) died during follow-up, despite the overall favorable prognosis.  \nConclusion This study underscores key clinicopathological differences between BOT subtypes and supports surgery as the cornerstone of treatment. Serous BOTs carry a higher risk of recurrence and advanced disease. Tailored surgical strategies and vigilant follow-up are essential, especially in fertility-preserving cases. Further multicenter studies are warranted to guide regional management.  \nKeywords Borderline ovarian tumors, Serous subtype, Mucinous subtype, Fertility-sparing surgery, Tumor recurrence  \n*Correspondence:  \nSaeed Baradwan  \n[dr.saeed_bardwan@yahoo.com](dr.saeed_bardwan@yahoo.com)  \n1Department of Obstetrics and Gynecology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia  \n2Department of Anatomic Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia 3Research Department, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecomm","cbCairQf51EUoF1K","https://ap.wps.com/l/cbCairQf51EUoF1K","pdf",1085298,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What distinguishes borderline ovarian tumors from invasive ovarian carcinomas?\",\"answer\":\"Borderline ovarian tumors show atypical epithelial proliferation but lack destructive stromal invasion, which supports their distinct classification and generally favorable prognosis.\"},{\"question\":\"Which clinicopathological features were most common in the reviewed Saudi cohort?\",\"answer\":\"Most patients were premenopausal, presented with stage I disease, and serous BOT was the predominant subtype. Fertility-sparing surgery was performed in a subset of cases.\"},{\"question\":\"How do serous and mucinous BOT subtypes differ in recurrence and related findings?\",\"answer\":\"Serous BOTs were significantly associated with bilateral tumors, higher FIGO stage, implants, and recurrence, whereas mucinous BOTs showed higher rates of appendectomy and positive peritoneal cytology.\"}]","A clinicopathological study of borderline ovarian tumors - insights from a tertiary care center in Saudi Arabia | PDF",1790106770,23,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf23e7d63ff504a0e2a946a5a182963d.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2dce8db98a6fcd4bf777ec052ba3a89a.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f2071511d74b0f093953e9bbc5cbbca.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d9fc5ae5ee7026bf3afe8b3392a009a.webp",980,1306]